American journal of cardiovascular disease最新文献

筛选
英文 中文
The occurrence of ST elevation myocardial infarction (STEMI) and non-STEMI in patients with post traumatic stress disorder (PTSD) using the large nationwide inpatient sample (NIS). 利用大型全国住院病人样本(NIS),研究创伤后应激障碍(PTSD)患者ST段抬高型心肌梗死(STEMI)和非STEMI的发生率。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-06-15 eCollection Date: 2024-01-01 DOI: 10.62347/YTCI7645
Abdullah Mohamed Niyas, Fathima Haseefa, Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mehrnoosh Hashemzadeh
{"title":"The occurrence of ST elevation myocardial infarction (STEMI) and non-STEMI in patients with post traumatic stress disorder (PTSD) using the large nationwide inpatient sample (NIS).","authors":"Abdullah Mohamed Niyas, Fathima Haseefa, Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mehrnoosh Hashemzadeh","doi":"10.62347/YTCI7645","DOIUrl":"10.62347/YTCI7645","url":null,"abstract":"<p><strong>Background: </strong>PTSD leads to increased levels of stress hormones and dysregulation of the autonomic nervous system which may trigger cardiac events. The goal of this study is to evaluate any association between PTSD and the occurrence of STEMI and NSTEMI using a large database.</p><p><strong>Method: </strong>Using the Nationwide Inpatient Sample (NIS) and ICD-9 codes from 2005 to 2014 (n=1,621,382), we performed a univariate chi-square analysis of in-hospital occurrence of STEMI and NSTEMI in patients greater than 40 years of age with and without PTSD. We also performed a multivariate analysis adjusting for baseline characteristics including age, gender, diabetes, race, hyperlipidemia, hypertension, and tobacco use.</p><p><strong>Results: </strong>The 2005-2014 dataset contained 401,485 STEMI patients (745, or 0.19%, with PTSD) and 1,219,897 NSTEMI patients (2,441, or 0.15%, with PTSD). In the 2005 dataset, 0.5% of PTSD patients had STEMI compared to 1.0% of non-PTSD patients (OR=0.46, 95% C.I., 0.36-0.59). Similarly, 0.6% of patients with PTSD and 2.2% of patients without PTSD had NSTEMI (OR=0.28, 95% C.I., 0.23-0.35). In the 2014 dataset, 0.3% of PTSD patients had STEMI compared to 0.7% of non-PTSD patients (OR=0.43, 95% C.I., 0.35-0.51). Similarly, 1.4% of patients with PTSD versus 2.9% of patients without PTSD had NSTEMI (OR=0.48, 95% C.I., 0.44-0.52). Similar trends were seen throughout the ten-year period. After adjusting for age, gender, diabetes, race, hyperlipidemia, hypertension, and tobacco use, PTSD was associated with a lower occurrence of STEMI (2005: OR=0.50, 95% C.I., 0.37-0.66; 2014: OR=0.35, 95% C.I., 0.29-0.43) and NSTEMI (2005: OR=0.44, 95% C.I., 0.34-0.57; 2014: OR=0.63, 95% C.I., 0.58-0.69).</p><p><strong>Conclusion: </strong>Using a large inpatient database, we did not find an increased occurrence of STEMI or NSTEMI in patients diagnosed with PTSD, suggesting that PTSD is not an independent risk factor for myocardial infarction.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 3","pages":"172-179"},"PeriodicalIF":1.3,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiogenic pulmonary edema - is it lone cardiogenic? "Missing link" between hemodynamic and other existing mechanisms. 心源性肺水肿--它是孤独的心源性肺水肿吗?血液动力学和其他现有机制之间的 "缺失环节"。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/YGQQ8696
Hamayak S Sisakian, Ani R Tavaratsyan
{"title":"Cardiogenic pulmonary edema - is it lone cardiogenic? \"Missing link\" between hemodynamic and other existing mechanisms.","authors":"Hamayak S Sisakian, Ani R Tavaratsyan","doi":"10.62347/YGQQ8696","DOIUrl":"10.62347/YGQQ8696","url":null,"abstract":"<p><p>The current traditional pathophysiologic concept of pulmonary edema of cardiogenic origin explains its development by a hydrostatic effect due to increased pulmonary capillary pressure resulting in fluid flux to alveolar and interstitial areas from capillaries. However, several experimental studies and clinical data of poor response to hemodynamic and diuretic treatment in many scenarios provide further evidence of the involvement of several other contributing factors to the development of cardiogenic pulmonary edema. Several experimental and clinical studies have found that sympathetic overactivity with elevated plasma catecholamine concentrations may play an important role in the development of cardiovascular-associated pulmonary edema. Catecholamine-induced pulmonary injury may be one of the key mechanisms in acute cardiogenic pulmonary edema triggering proinflammatory cytokine overactivation, oxidative stress and myocardial injury. In the everyday treatment of acute heart failure, physicians should consider the possibility of other noncardiogenic mechanisms involved in the progression of acute pulmonary edema, particularly catecholamine overactivity, lymphatic drainage, inflammatory and oxidative stress, high surfactant protein. The classic, hemodynamic treatment approach in pulmonary edema with the coexistence of other contributing factors may not provide adequate clinical benefit during treatment.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"81-89"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular outcomes of emergent vs elective transcatheter aortic valve replacement in severe aortic stenosis: regression matched meta-analysis. 重度主动脉瓣狭窄患者急诊与择期经导管主动脉瓣置换术的心血管预后:回归匹配荟萃分析。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/PORE5631
Yasar Sattar, Mohammad Hamza, Farah Yasmin, Sidra Jabeen, Neel Patel, Syed Ishaq, Bandar Alyami, Hassan Ul Hussain, Syeda Tayyaba Rehan, Syed Hasan Shuja, Zayeema Khan, Yasemin Bahar, Islam Y Elgendy, Karthik Gonuguntla, Harshith Thyagaturu, Akram Kawsara, Kevin Felpel, Ramesh Daggubati, M Chadi Alraies
{"title":"Cardiovascular outcomes of emergent vs elective transcatheter aortic valve replacement in severe aortic stenosis: regression matched meta-analysis.","authors":"Yasar Sattar, Mohammad Hamza, Farah Yasmin, Sidra Jabeen, Neel Patel, Syed Ishaq, Bandar Alyami, Hassan Ul Hussain, Syeda Tayyaba Rehan, Syed Hasan Shuja, Zayeema Khan, Yasemin Bahar, Islam Y Elgendy, Karthik Gonuguntla, Harshith Thyagaturu, Akram Kawsara, Kevin Felpel, Ramesh Daggubati, M Chadi Alraies","doi":"10.62347/PORE5631","DOIUrl":"10.62347/PORE5631","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve replacement (TAVR) has been highly increased as the recommended option for patients with a high surgical risk. This study aims to commit a systematic review and meta-analysis to assess the outcomes in severe aortic stenosis patients following emergency transcatheter aortic valve replacement (emergent TAVR) compared to elective TAVR or eBAV followed by elective TAVR.</p><p><strong>Methods: </strong>We conducted a systematic literature search of PubMed, Embase, Cochrane CENTRAL, CINAHL, Science Direct, and Google Scholar. We included nine studies in the latest analysis that reported the desired outcomes. Outcomes were classified into primary outcomes: 30-day all-cause mortality and 30-day readmission rate, and secondary outcomes, which were further divided into (a) peri-procedural outcomes, (b) vascular outcomes, and (c) renal outcomes. Statistical analysis was performed using Stata v.17 (College State, TX) software.</p><p><strong>Results: </strong>A total of 44,731 patients with severe aortic stenosis were included (emergent TAVR n = 4502; control n = 40045). 30-day mortality was significantly higher in the emergent TAVR group (OR: 2.62; 95% CI = 1.76-3.92; P < 0.01). Regarding post-procedural outcomes, the length of stay was significantly higher in the emergent TAVR group (Hedges's g: +4.73 days; 95% CI = +3.35 to +6.11; P < 0.01). With respect to vascular outcomes, they were similar in both groups. Regarding renal outcomes, both acute kidney injury (OR: 2.52; 95% CI = 1.59-4.00; P < 0.01) and use of renal replacement therapy (OR: 2.33; 95% CI = 1.87-2.91; P < 0.01) were significantly higher in emergent TAVR group as compared to the control group.</p><p><strong>Conclusion: </strong>Our study demonstrated that despite increased 30-day mortality and worse renal outcomes, the post-procedural outcomes were similar in emergent and elective TAVR groups. The increased mortality and worse renal outcomes are likely due to hemodynamic instability in the emergent group. The similarity of post-procedural outcomes is evidence of the safety of TAVR even in emergent settings.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"54-69"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Young patient presenting with cardiogenic shock and refractory ventricular tachycardia: a case of unsuspected arrhythmogenic cardiomyopathy leading to urgent heart transplantation. 出现心源性休克和难治性室性心动过速的年轻患者:一例导致紧急心脏移植的未被发现的心律失常性心肌病。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/TAEY9817
Benoit Yu, Nickolas Poulakos, Alexander Beaulieu-Shearer, Pierre Yves Turgeon, Sylvain Trahan, David Belzile, Mario Sénéchal
{"title":"Young patient presenting with cardiogenic shock and refractory ventricular tachycardia: a case of unsuspected arrhythmogenic cardiomyopathy leading to urgent heart transplantation.","authors":"Benoit Yu, Nickolas Poulakos, Alexander Beaulieu-Shearer, Pierre Yves Turgeon, Sylvain Trahan, David Belzile, Mario Sénéchal","doi":"10.62347/TAEY9817","DOIUrl":"10.62347/TAEY9817","url":null,"abstract":"<p><p>Arrhythmogenic right ventricular cardiomyopathy is an important differential diagnosis in young patients presenting with palpitations and/or dyspnea and must be appropriately investigated. A 23-year-old man presented with cardiogenic shock and monomorphic ventricular tachycardia. He reported palpitations and progressive dyspnea for more than two years, but those symptoms were attributed to anxiety without any further investigation by his family physician. Investigations after the catastrophic presentation in our center suggested terminal right-sided heart failure with severe hepatic insufficiency and acute kidney injury. The patient benefited from extracorporeal membrane oxygenation, followed by an urgent heart transplant 16 days later after the exclusion of liver cirrhosis. Histopathologic analysis of the explanted heart confirmed arrhythmogenic cardiomyopathy.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"121-127"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A risk predictive model for determining the severity of coronary artery lesions in older postmenopausal women with coronary heart disease. 用于确定患有冠心病的绝经后老年妇女冠状动脉病变严重程度的风险预测模型。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/TWBY9801
Wei Wen, Qing Ye, Li-Xiang Zhang, Li-Kun Ma
{"title":"A risk predictive model for determining the severity of coronary artery lesions in older postmenopausal women with coronary heart disease.","authors":"Wei Wen, Qing Ye, Li-Xiang Zhang, Li-Kun Ma","doi":"10.62347/TWBY9801","DOIUrl":"10.62347/TWBY9801","url":null,"abstract":"<p><strong>Objective: </strong>To determine the risk factors affecting the severity of coronary artery disease (CAD) in older postmenopausal women with coronary heart disease (CHD) and to construct a personalized risk predictive model.</p><p><strong>Methods: </strong>In this cohort study, clinical records of 527 female patients aged ≥60 with CHD who were hospitalized in the First Affiliated Hospital of the University of Science and Technology of China from March 2018 to February 2019 were analyzed retrospectively. The severity of CAD was determined using the Gensini scores that are based on coronary angiography findings. Patients with Gensini scores ≥40 and <40 were divided into high-risk (n=277) and non-high-risk groups (n=250), respectively. Logistic regression analysis was used to assess independent predictors of CAD severity. The nomogram prediction model of CAD severity was plotted by the R software. The area under the receiver operating characteristic (ROC) and calibration curves were used to evaluate the predictive efficiency of the nomogram model, and the decision curve analysis (DCA) was used to assess the clinical applicability of the nomogram model.</p><p><strong>Results: </strong>Multivariate analysis showed that high-sensitivity C-reactive protein, RBC count, WBC count, BMI, and diabetes mellitus were independent risk factors associated with CAD severity in older menopausal women (P<0.05); the area under the ROC curve of the nomogram constructed based on the independent risk factors was 0.846 (95% CI: 0.756-0.937). The area under the ROC curve after internal validation of the nomogram by the Bootstrap method after resampling 1000 times was 0.840 (95% CI: 0.741-0.923). The calibration curve suggested that the nomogram had an excellent predictive agreement, and the DCA curve indicated that the net benefit of applying the nomogram was significantly higher than that of the \"no intervention\" and \"all intervention\" methods when the risk probability of patients with high-risk CAD severity was 0.30-0.81.</p><p><strong>Conclusion: </strong>A personalized risk assessment model was constructed based on the risk factors of severe CAD in older menopausal women with CHD, which had good prediction efficiency based on discrimination, calibration, and clinical applicability evaluation indicators. This model could assist cardiology medical staff in screening older menopausal women with CHD who are at a high risk of severe CAD to implement targeted interventions.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"106-115"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the use of antiviral drugs in HIV patients with cardiovascular diseases and how to reduce the incidence of cardiac events in these patients. 评估抗病毒药物在患有心血管疾病的艾滋病患者中的使用情况,以及如何降低这些患者的心脏事件发生率。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/OBXQ4787
Azad Mojahedi
{"title":"Evaluating the use of antiviral drugs in HIV patients with cardiovascular diseases and how to reduce the incidence of cardiac events in these patients.","authors":"Azad Mojahedi","doi":"10.62347/OBXQ4787","DOIUrl":"10.62347/OBXQ4787","url":null,"abstract":"<p><p>Globally, the incidence of newly diagnosed human immunodeficiency virus (HIV) infections is concerning. Despite enhancing the quality of life for this patient population, antiretroviral therapy (ART) is linked to an increased risk of cardiovascular disease (CVD). In people living with HIV (PLWH) undergoing ART, recent research has demonstrated that the use of statins and aspirin (ASA) can reduce the incidence or progression of CVD. However, research has demonstrated that interactions may occur when these medications are used concurrently in the treatment regimen of PLWH. Therefore, we conclude this systematic review to evaluate the use of ART in HIV individuals with CVD and also the effect of adding ASA and statins to ART for reducing the cardiac adverse events.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"70-80"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suspected colchicine-induced late myocardial rupture occurring after the late presentation of acute inferior ST-elevation myocardial infarction. 急性下ST段抬高型心肌梗死晚期表现后发生的疑似秋水仙碱诱发的晚期心肌破裂。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/FXLN8938
Abdullah Mohamed Niyas, Fathima Haseefa, Jordy Charles Cox, Mohammad Reza Movahed
{"title":"Suspected colchicine-induced late myocardial rupture occurring after the late presentation of acute inferior ST-elevation myocardial infarction.","authors":"Abdullah Mohamed Niyas, Fathima Haseefa, Jordy Charles Cox, Mohammad Reza Movahed","doi":"10.62347/FXLN8938","DOIUrl":"10.62347/FXLN8938","url":null,"abstract":"<p><p>Colchicine is one of the established drugs of choice for post-myocardial infarction (MI) induced pericarditis, given its anti-inflammatory properties. Recently, colchicine received FDA approval for secondary prevention of atherosclerotic cardiovascular disease, which leads to concerns regarding its anti-healing effects on myocardial tissue post-infarction. We present a case of a suspected colchicine-induced myocardial rupture in an elderly male, who presented with a syncopal episode while on colchicine three weeks after the late presentation of infero-posterior ST-elevation myocardial infarction.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"116-120"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic blockade of the activation of 26S proteasomes by PKA is well tolerated by mice at baseline. 基因阻断 PKA 对 26S 蛋白酶体的激活,小鼠在基线期的耐受性很好。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/NSWR6869
Liuqing Yang, Md Salim Ahammed, Penglong Wu, Jack O Sternburg, Jinbao Liu, Xuejun Wang
{"title":"Genetic blockade of the activation of 26S proteasomes by PKA is well tolerated by mice at baseline.","authors":"Liuqing Yang, Md Salim Ahammed, Penglong Wu, Jack O Sternburg, Jinbao Liu, Xuejun Wang","doi":"10.62347/NSWR6869","DOIUrl":"10.62347/NSWR6869","url":null,"abstract":"<p><strong>Objective: </strong>Proteasome activation by the cAMP-dependent protein kinase (PKA) was long suggested and recent studies using both cell cultures and genetically engineered mice have established that direct phosphorylation of RPN6/PSMD11 at Serine14 (pS14-RPN6) mediates the activation of 26S proteasomes by PKA. Genetic mimicry of pS14-RPN6 has been shown to be benign at baseline and capable of protecting against cardiac proteinopathy in mice. Here we report the results from a comprehensive baseline characterization of the Rpn6<sup>S14A</sup> mice (S14A), the first animal model of genetic blockade of the activation of 26S proteasomes by PKA.</p><p><strong>Method: </strong>Wild type and homozygous S14A littermate mice were subjected to serial M-mode echocardiography at 1 through 7 months of age, to left ventricular (LV) catheterization via the carotid artery for assessment of LV mechanical performance, and to cardiac gravimetric analyses at 26 weeks of age. Mouse mortality and morbidity were monitored daily for up to one year. Males and females were studied in parallel.</p><p><strong>Results: </strong>Mice homozygous for S14A were viable and fertile and did not show discernible developmental abnormalities or increased mortality or morbidity compared with their Rpn6 wild type littermates by at least one year of age, the longest cohort observed thus far. Neither serial echocardiography nor hemodynamic assessments detected a remarkable difference in cardiac morphometry and function between S14A and wild type littermate mice. No cardiac gravimetric difference was observed.</p><p><strong>Conclusion: </strong>The findings of the present study indicate that genetic blockade of the activation of 26S proteasomes by PKA is well tolerated by mice at baseline. Therefore, the S14A mouse provides a desirable genetic tool for further investigating the in vivo pathophysiological and pharmacological significance of pS14-RPN6.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"90-105"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Procedural and cardiovascular outcomes of geriatric vs non-geriatric patients undergoing permanent pacemaker implantation - a nationwide cohort analysis. 接受永久起搏器植入术的老年病人与非老年病人的手术和心血管预后--全国范围内的队列分析。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/FIRV6475
Ayesha Shaik, Madhuwani Rojulpote, Nicholas Roma, Neel Patel, Yasar Sattar, Harshith Thyagaturu, Muchi Ditah Chobufo, Raahat Bansal, Anas Alharbi, Amro Taha, Sameer Raina, Karthik Gonuguntla
{"title":"Procedural and cardiovascular outcomes of geriatric vs non-geriatric patients undergoing permanent pacemaker implantation - a nationwide cohort analysis.","authors":"Ayesha Shaik, Madhuwani Rojulpote, Nicholas Roma, Neel Patel, Yasar Sattar, Harshith Thyagaturu, Muchi Ditah Chobufo, Raahat Bansal, Anas Alharbi, Amro Taha, Sameer Raina, Karthik Gonuguntla","doi":"10.62347/FIRV6475","DOIUrl":"10.62347/FIRV6475","url":null,"abstract":"<p><strong>Background: </strong>Permanent pacemaker implantation is increasing exponentially to treat atrio-ventricular block and symptomatic bradyarrhythmia. Despite being a minor surgery, immediate complications such as pocket infection, pocket hematoma, pneumothorax, hemopericardium, and lead displacement do occur.</p><p><strong>Methods: </strong>The Nationwide Inpatient Sample was queried from 2016 to 2018 to identify patients with pacemakers using ICD-10 procedure code. The Chi-square test was used for statistical analysis.</p><p><strong>Results: </strong>The sample size consisted of 443,460 patients with a pacemaker, 26% were <70 years (male 57%, mean age of (60.6±9.7) yr, Caucasian 70%) and 74% were ≥70 years (male 50%, mean age of (81.4±5.9) yr, Caucasian 79%). Upon comparison of rates in the young vs elderly: mortality (1.6% vs 1.5%; P<0.01), obesity (26% vs 13%; P<0.001), coronary artery disease (40% vs 49%; P<0.001), HTN (74% vs 87%; P<0.01), anemia (4% vs 5%; P<0.01), atrial fibrillation (34% vs 49%; P<0.01), peripheral artery disease (1.7% vs 3%; P<0.01), CHF (31% vs 39%; P<0.001), diabetes (31% vs 27.4%; P<0.01), vascular complications (1.1% vs 1.2%; P<0.01), pocket hematoma (0.5% vs 0.8%; P<0.01), AKI (16% vs 21%; P<0.01), hemopericardium (0.1% vs 0.1%; P = 0.1), hemothorax (0.3% vs 0.2%; P<0.01), cardiac tamponade (0.4% vs 0.5%; P<0.01), pericardiocentesis (0.4% vs 0.4%; P<0.01), cardiogenic shock (4% vs 2.3%; P<0.01), respiratory complications (1.9% vs 0.9%; P<0.01), mechanical ventilation (5.1% vs 2.9%; P<0.01); post-op bleed (0.5% vs 0.3%; P<0.01), need for transfusion (4.8% vs 3.8%; P<0.01), severe sepsis (0.6% vs 0.5%; P<0.01 ), septic shock (2% vs 1%; P<0.01), bacteraemia (0.8% vs 0.4%; P<0.01), lead dislodgement (1.4% vs 1.1%; P<0.01).</p><p><strong>Conclusions: </strong>Our study revealed that the overall complication rates were lower in the elderly despite higher co-morbidities. This aligns with previous studies which showed lower rates in the elderly. Hence providers should not hesitate to provide guideline driven pacemaker placement in the elderly especially in patients with good life expectancy.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 2","pages":"128-135"},"PeriodicalIF":1.3,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between blood albumin and hospital death and long-term death in ICU patients with heart failure: data from the medical information mart for intensive care III database. 重症监护病房心力衰竭患者血白蛋白与住院死亡和长期死亡之间的相关性:重症监护医疗信息集市 III 数据库的数据。
IF 1.3
American journal of cardiovascular disease Pub Date : 2024-02-20 eCollection Date: 2024-01-01
Xin Wan, Ling Gu, Huogen Liu, Hailin Shu, Ying Liu, Rijin Huang, Yundi Shi
{"title":"Correlation between blood albumin and hospital death and long-term death in ICU patients with heart failure: data from the medical information mart for intensive care III database.","authors":"Xin Wan, Ling Gu, Huogen Liu, Hailin Shu, Ying Liu, Rijin Huang, Yundi Shi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Elevated circulating levels of albumin (ALB) are often associated with improved prognosis in patients with heart failure (HF). However, investigations of its association with hospital death and long-term death in HF patients in the intensive care unit (ICU) are limited.</p><p><strong>Aim: </strong>We examined whether increased blood ALB levels (first value at admission and maximum and minimum values in the ICU) were related to a greater risk of hospital death and long-term death in ICU patients with HF.</p><p><strong>Methods: </strong>For the first time, we analyzed 4084 ICU patients with HF admitted to the ICU in The Medical Information Mart for Intensive Care III (MIMIC-III) database.</p><p><strong>Results: </strong>Among 4084 HF patients, 774 (18.95%), 1056 (25.86%) and 1720 (42.12%) died in the hospital, within 30 days and 1 year, respectively. We conducted a logistic regression analysis and found significant inverse associations between blood ALB concentration and risk of hospital death, 30-day death and 1-year death when the covariates including age, sex, myocardial infarction (MI), hypertension, diabetes, valvular diseases, atrial fibrillation, stroke and chronic kidney disease (CKD) were adjusted. We additionally used a smooth curve for univariate analysis to establish an association between blood ALB concentration and death risk. Surprisingly, we observed U-shaped correlations between blood ALB concentration and hospital mortality, 30-day mortality and 1-year mortality. We found that the \"inflection point\" for the blood ALB concentration at the lowest risk of death was 3.5 g/dL. We further observed that a higher blood ALB concentration (albumin-max) did not contribute to a reduced risk of death (hospital death, 30-day death and 1-year death) in HF patients with an albumin concentration >3.5 g/dL.</p><p><strong>Conclusions: </strong>A lower blood ALB concentration contributed to a greater risk of hospital death and long-term death in HF patients admitted to the ICU, further suggesting that nutritional support in the ICU is highly important for improving the short-term and long-term mortality of HF patients. However, in HF patients without hypoproteinaemia (>3.5 g/dL), the impact of increased serum ALB on patient prognosis still needs to be demonstrated.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 1","pages":"29-39"},"PeriodicalIF":1.3,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140142617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信